Pfizer loses $107.5m AstraZeneca verdict after voiding cancer patents

AstraZeneca successfully argued that “no reasonable jury” could find it had infringed the patents-in-suit claiming lung cancer patents | Reprieve comes after misconduct allegations against a Pfizer unit fell flat earlier this month.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pfizer fends off misconduct claims to keep $107.5m award

8 August 2024 A Delaware jury found AstraZeneca liable for induced infringement of a cancer treatment in May | Pharma company levelled allegations of "unclean hands" and "patent misuse" at Pfizer unit.

Americas

Pfizer sues Chinese pharma firm over prostate cancer drug

6 August 2024 Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.

More features

How 'Boehringer' sets preliminary relief threshold for generics

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Pfizer loses $107.5m AstraZeneca verdict after voiding cancer patents

More on this story

Editor's picks

Editor's picks

More features